WO1998032463A3 - Lyophilizate of lipid complex of water insoluble porphyrins - Google Patents

Lyophilizate of lipid complex of water insoluble porphyrins Download PDF

Info

Publication number
WO1998032463A3
WO1998032463A3 PCT/US1998/000033 US9800033W WO9832463A3 WO 1998032463 A3 WO1998032463 A3 WO 1998032463A3 US 9800033 W US9800033 W US 9800033W WO 9832463 A3 WO9832463 A3 WO 9832463A3
Authority
WO
WIPO (PCT)
Prior art keywords
lyophilizate
lipid complex
water insoluble
porphyrins
insoluble porphyrins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/000033
Other languages
French (fr)
Other versions
WO1998032463A2 (en
Inventor
Mathew Cherian
Shireesh Prakash Apte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP53198698A priority Critical patent/JP2001511128A/en
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Priority to AU60152/98A priority patent/AU6015298A/en
Priority to AT98903356T priority patent/ATE261736T1/en
Priority to DE69822496T priority patent/DE69822496T2/en
Priority to EP98903356A priority patent/EP1030686B1/en
Publication of WO1998032463A2 publication Critical patent/WO1998032463A2/en
Publication of WO1998032463A3 publication Critical patent/WO1998032463A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition comprising a porphyrin and a phospholipid; a method for preparing a lyophilizate of a lipid complex and a porphyrin; and a method of photodynamic treatment of a patient in need of such treatment are disclosed.
PCT/US1998/000033 1997-01-28 1998-01-28 Lyophilizate of lipid complex of water insoluble porphyrins Ceased WO1998032463A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP53198698A JP2001511128A (en) 1997-01-28 1998-01-23 Lyophilized product of lipid complex of water-insoluble porphyrin
AU60152/98A AU6015298A (en) 1997-01-28 1998-01-28 Lyophilizate of lipid complex of water insoluble porphyrins
AT98903356T ATE261736T1 (en) 1997-01-28 1998-01-28 LIPID COMPLEX LYOPHILIZATE OF WATER-INSOLUBLE PORPHYRINS
DE69822496T DE69822496T2 (en) 1997-01-28 1998-01-28 LIPID COMPLEX-LYOPHILISATE OF WATER-INSOLUBLE PORPHYRINES
EP98903356A EP1030686B1 (en) 1997-01-28 1998-01-28 Lyophilizate of lipid complex of water insoluble porphyrins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78956697A 1997-01-28 1997-01-28
US08/789,566 1997-01-28

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09341932 A-371-Of-International 1999-07-20
US77827901A Continuation 1999-07-20 2001-02-07
US09/970,596 Continuation US6608050B2 (en) 1999-07-20 2001-10-04 Lyophilizate of lipid complex of water insoluble porphyrins

Publications (2)

Publication Number Publication Date
WO1998032463A2 WO1998032463A2 (en) 1998-07-30
WO1998032463A3 true WO1998032463A3 (en) 1998-10-22

Family

ID=25148009

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/000033 Ceased WO1998032463A2 (en) 1997-01-28 1998-01-28 Lyophilizate of lipid complex of water insoluble porphyrins

Country Status (9)

Country Link
EP (1) EP1030686B1 (en)
JP (1) JP2001511128A (en)
AT (1) ATE261736T1 (en)
AU (1) AU6015298A (en)
DE (1) DE69822496T2 (en)
DK (1) DK1030686T3 (en)
ES (1) ES2218805T3 (en)
PT (1) PT1030686E (en)
WO (1) WO1998032463A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20080269184A1 (en) * 2004-03-04 2008-10-30 Makoto Yuasa Niosome Having Metal Porphyrin Complex Embedded Therein, Process For Producing The Same And Drug With The Use Thereof
JP4591820B2 (en) * 2005-01-31 2010-12-01 株式会社ケムコ Chemiluminescent reagent
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
HRP20130259T1 (en) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. SUSPENSION FORMULATIONS OF INSULINOTROPIC PEPTIDES AND THEIR USE
SMT201700583T1 (en) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP3019559A4 (en) 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
AU2017240154B2 (en) 2016-04-01 2021-08-12 Sony Group Corporation Ultra bright dimeric or polymeric dyes
US9851359B2 (en) 2016-04-06 2017-12-26 Sony Corporation Of America Ultra bright dimeric or polymeric dyes with spacing linker groups
KR102526802B1 (en) 2016-05-11 2023-05-02 소니그룹주식회사 Ultra high brightness dimeric or polymeric dyes
RU2760007C2 (en) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Polypeptides selective to glucagon receptors and their application methods
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
JP7312929B2 (en) 2016-07-29 2023-07-24 ソニーグループ株式会社 Superbright dimer or polymer dyes and methods for their preparation
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent
CN111093711A (en) 2017-10-05 2020-05-01 索尼公司 Programmable dendrimers
JP7551056B2 (en) 2017-10-05 2024-09-17 ソニーグループ株式会社 Programmable polymer drugs
CN111836645A (en) 2017-11-16 2020-10-27 索尼公司 Programmable Polymeric Drugs
CN111565756A (en) 2018-01-12 2020-08-21 索尼公司 Polymers with Rigid Spacer Groups Containing Biologically Active Compounds
US12194104B2 (en) 2018-01-12 2025-01-14 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
EP3737419B1 (en) 2018-01-12 2024-04-10 Sony Group Corporation Phosphoalkyl polymers comprising biologically active compounds
US11874280B2 (en) 2018-03-19 2024-01-16 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
KR102864292B1 (en) 2018-03-21 2025-09-26 소니그룹주식회사 Polymeric tandem dyes having linker groups
US12006438B2 (en) 2018-06-27 2024-06-11 Sony Group Corporation Polymeric dyes with linker groups comprising deoxyribose
EP3820944A1 (en) 2018-07-13 2021-05-19 Sony Corporation Polymeric dyes having a backbone comprising organophosphate units
WO2021062176A2 (en) 2019-09-26 2021-04-01 Sony Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
WO2022125564A1 (en) 2020-12-07 2022-06-16 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569113A1 (en) * 1992-02-05 1993-11-10 Quadra Logic Technologies Inc. Liposome compositions of porphyrin photosensitizers
US5277913A (en) * 1991-09-09 1994-01-11 Thompson David H Liposomal delivery system with photoactivatable triggered release
US5389378A (en) * 1990-08-17 1995-02-14 The Liposome Company, Inc. Benzoporphyrin vesicles and their use in photodynamic therapy
EP0720853A1 (en) * 1995-01-05 1996-07-10 Ciba-Geigy Ag Topical administrable zinc phtalocyanine compositions
WO1996032094A1 (en) * 1995-04-11 1996-10-17 Pharmacia & Upjohn Ab Emulsion suitable for administering a poorly water-soluble photosensitizing compound and use thereof
US5707608A (en) * 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389378A (en) * 1990-08-17 1995-02-14 The Liposome Company, Inc. Benzoporphyrin vesicles and their use in photodynamic therapy
US5277913A (en) * 1991-09-09 1994-01-11 Thompson David H Liposomal delivery system with photoactivatable triggered release
EP0569113A1 (en) * 1992-02-05 1993-11-10 Quadra Logic Technologies Inc. Liposome compositions of porphyrin photosensitizers
EP0720853A1 (en) * 1995-01-05 1996-07-10 Ciba-Geigy Ag Topical administrable zinc phtalocyanine compositions
WO1996032094A1 (en) * 1995-04-11 1996-10-17 Pharmacia & Upjohn Ab Emulsion suitable for administering a poorly water-soluble photosensitizing compound and use thereof
US5707608A (en) * 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANNON J B: "PHARMACEUTICS AND DRUG DELIVERY ASPECTS OF HEME AND PORPHYRIN THERAPY", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 82, no. 5, 1 May 1993 (1993-05-01), pages 435 - 446, XP000368106 *
GREGORY B W ET AL: "Interfacial complexation of phospholipid Langmuir monolayers with water-soluble porphyrins and phthalocyanines: An X-ray reflectivity study", THIN SOLID FILMS, vol. 284-285, 15 September 1996 (1996-09-15), pages 849-853, XP004078249 *
KUZELOVA K ET AL: "Interactions of dicarboxylic porphyrins with unilamellar lipidic vesicles: drastic effects of pH and cholesterol on kinetics.", BIOCHEMISTRY, SEP 5 1995, 34 (35) P11245-55, UNITED STATES, XP002070076 *
MAYHEW E ET AL: "LIPID-ASSOCIATED METHYLPHEOPHORBIDE-A (HEXYL-ETHER) AS A PHOTODYNAMIC AGENT IN TUMOR-BEARING MICE", PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 58, no. 6, 1 January 1993 (1993-01-01), pages 845 - 851, XP000564985 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Also Published As

Publication number Publication date
DE69822496T2 (en) 2005-03-03
WO1998032463A2 (en) 1998-07-30
ATE261736T1 (en) 2004-04-15
JP2001511128A (en) 2001-08-07
ES2218805T3 (en) 2004-11-16
AU6015298A (en) 1998-08-18
EP1030686A2 (en) 2000-08-30
EP1030686B1 (en) 2004-03-17
DE69822496D1 (en) 2004-04-22
PT1030686E (en) 2004-06-30
DK1030686T3 (en) 2004-04-13

Similar Documents

Publication Publication Date Title
WO1998032463A3 (en) Lyophilizate of lipid complex of water insoluble porphyrins
AU9486698A (en) Light delivery catheter and pdt treatment method
CA2193502A1 (en) Sphingosomes for enhanced drug delivery
AU4611199A (en) Porphyrin derivatives and their use in photodynamic therapy and mri diagnosis
AU1312099A (en) Apparatus and method for (in vivo) delivery of therapeutic agents
AU9028798A (en) Method of improving drug treatment
AU8428898A (en) Apparatus and methods to monitor photodynamic therapy (pdt)
EP1022945A4 (en) Method and formulation for treating vascular disease
AU1805499A (en) Method and apparatus for delivery of therapeutic agents to the heart
AU4477800A (en) Method and apparatus for diseased tissue diagnosis
PL333284A1 (en) Methods for medicinal treatment of skin pigmentation
GR3023906T3 (en) Liposome compositions of porphyrin photosensitizers
AU7678096A (en) Therapeutic medical garments for scars and process
AU2990695A (en) Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer
MY113203A (en) Lyophilizate of lipid complex of water insoluble camptothecins
WO1999044608A8 (en) New use
AU2947097A (en) Use of green porphyrins in the manufacture of a medicament in the treatment of atherosclerosis without purposeful irradiation of the porphyrin derivatives
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
SI1035859T1 (en) The use of phospholipid complexes of extracts of vitis vinifera as anti-atherosclerotic agents
AU1395499A (en) Methods for treatment of tumors and tumor cells using (ex vivo) activated t cells
ZA9710413B (en) Compliance package and method of improving or aiding patient compliance for complex drug regimens.
AU7486898A (en) Global medical treatment method and apparatus
AU8732598A (en) Device and method for irradiating a patient's eye for photodynamic therapy
ZA982369B (en) Dihydropyrazino[1,2-a]indol-1-one derivatives their preparation and their use in therapy
EP1007050A4 (en) Method for treating substance abuse

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 531986

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09341932

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998903356

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1998903356

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1998903356

Country of ref document: EP